Griffin Securities Starts Ligand Pharma (LGND) at Buy; Recent Decline in Share Price Presents A Buying Opportunity
Tweet Send to a FriendGet Alerts LGND Hot Sheet
Price: $28.01 +4.95%
Rating Summary:
3 Buy, 1 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 35 | New: 23
Rating Summary:
3 Buy, 1 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 35 | New: 23
Trade LGND Now!
Griffin Securities initiates coverage on Ligand Pharma (NASDAQ: LGND) with a Buy. PT $18.00.
Griffin analyst said, "Ligand’s investments are about to pay off handsomely: 1)Promacta sales are rising rapidly around the world and new indications are under development. The thrombocytopenia drug is gaining market share for ITP as the drug has entered new territories around the world and a new indication is likely – hepatitis C. 2) The Captisol platform opens new opportunities to partner with other drug companies at no risk. The modified cyclodextrin has passed regulatory muster and numerous compounds now in clinical trials use it to ensure proper bioavailability. 3) One drug may get an early approval. Onyx has submitted an NDA for carfilzomib for multiple myeloma based on Phase 2 data that has looked impressive."
For an analyst ratings summary and ratings history on Ligand Pharma click here. For more ratings news on Ligand Pharma click here.
Shares of Ligand Pharma closed at $10.59 yesterday, with a 52 week range of $1.52-$16.24.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Griffin analyst said, "Ligand’s investments are about to pay off handsomely: 1)Promacta sales are rising rapidly around the world and new indications are under development. The thrombocytopenia drug is gaining market share for ITP as the drug has entered new territories around the world and a new indication is likely – hepatitis C. 2) The Captisol platform opens new opportunities to partner with other drug companies at no risk. The modified cyclodextrin has passed regulatory muster and numerous compounds now in clinical trials use it to ensure proper bioavailability. 3) One drug may get an early approval. Onyx has submitted an NDA for carfilzomib for multiple myeloma based on Phase 2 data that has looked impressive."
For an analyst ratings summary and ratings history on Ligand Pharma click here. For more ratings news on Ligand Pharma click here.
Shares of Ligand Pharma closed at $10.59 yesterday, with a 52 week range of $1.52-$16.24.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Topeka Capital Starts Laredo Petroleum (LPI) at Buy, Assets 'Undervalued'
- Jefferies Starts Cempra, Inc. (CEMP) at Buy
- Barclays Starts Verizon Communications (VZ) at Overweight
Create E-mail Alert Related Categories
New Coverage
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
